Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekten af ​​Alphanate FVIII/VWF-koncentrat hos type 3 Von Willebrand-patienter

15. september 2026 opdateret af: Grifols Biologicals, LLC

En post-marketing observationsundersøgelse for at vurdere effektiviteten og sikkerheden af ​​FVIII/VWF-komplekset (Human), Alphanate®, til forebyggelse af overdreven blødning under kirurgi hos forsøgspersoner med medfødt type 3 Von Willebrands sygdom

To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

For the treatment of surgical procedures the intended dose of Alphanate® will be given as a single dose or as multiple doses over several days, depending on the clinical situation, and according to the Full Prescribing Information guideline and the investigator's judgment. For each treated event, the subject's treatment period will be finished when, in the opinion of the local Investigator, the participating subject would not benefit from further infusions of the study concentrate.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

4

Fase

  • Fase 4

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

7 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female 7 years of age or older
  2. The subject has been diagnosed of inherited VWD of Type 3 as determined by subject's medical records.
  3. The subject needs a surgical procedure (at least 10 surgical procedures have to be considered as "Major" according to the criteria of the protocol).
  4. The subject is expected to respond to exogenously administered FVIII/VWF according to Investigator's judgment.
  5. The subject freely gives written informed consent. Subjects who are not legally permitted to provide written consent must sign a form of assent for study participation, and written consent must be provided by a parent or legal guardian.

Exclusion Criteria:

  1. The subject has been diagnosed of Type 1, Type 2, or acquired VWD.
  2. The subject is known to have history of intolerance to any Alphanate® containing substance.
  3. The subject is known to have history of anaphylactic reaction(s) to blood or blood components.
  4. Liver function tests (AST, ALT, bilirubin) > 2.5 x upper limit of normal (ULN).
  5. Renal function test (creatinine) > 1.5 x ULN.
  6. The subject is known or suspected to have present or past inhibitor activity (antibodies) directed against FVIII or VWF.
  7. The subject is known to abuse alcohol or illicit drug use within the past 12 months.
  8. The subject is participating in another clinical study involving an investigational treatment, or participated within the past 4 weeks. Studies consisting of data and blood sampling collections on a regular or long-term basis are exempt from this exclusion.
  9. The subject is unlikely to adhere to the protocol requirements of the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Coagulation FVIII/VWF

Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT

A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.

Andre navne:
  • Alphanate® Faktor VIII/VWF koncentrat (menneske)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Investigator Overall Rating as a Measure of the Overall Treatment Outcome for Each Treated Surgical Procedure
Tidsramme: Up to 30 days

The local Investigator to rate the replacement treatment outcome (Investigator Overall Rating - Verbal Rating Scale) as a measure of overall clinical efficacy for each treated event.

It is rated using a 2-point Verbal Rating Scale as: Excellent/Good and Poor/None.

Up to 30 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Surgical Procedures at Both Visits Rated as Excellent/Good by the Investigator
Tidsramme: Day 0 (surgery day) and Day 1 (post-surgery day)

The number of surgical procedures rated by the local Investigator for the treatment outcomes at both visits.

Day 0 (surgery day) and Day 1 (post-surgery day)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Sandra Camprubi, Instituto Grifols, S.A.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. juli 2008

Primær færdiggørelse (Faktiske)

6. februar 2012

Studieafslutning (Faktiske)

6. februar 2012

Datoer for studieregistrering

Først indsendt

7. november 2007

Først indsendt, der opfyldte QC-kriterier

7. november 2007

Først opslået (Anslået)

8. november 2007

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner